University of California, San Francisco | HDFCCC - Hematopoietic Malignancies is a clinical research site located in San Francisco, California, United States 94158.
Crixeo Health Trust Score: 63/100 (FAIR). This profile has not yet been claimed by the site owner.
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies has participated in 4 clinical trials with 2 currently active.
Therapeutic areas: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms.
Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc..
Trust Score: 63/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies has a Crixeo Trust Score of 63/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies has 4 clinical trials on record, with 2 currently active. Their work covers Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms.
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.